-
Dra. Cristina Canal, Action Chair to coordinate European activity in Therapeutical applications of Cold Plasma
Dr. Cristina Canal (IRSJD) coordinates the "PlasTHER COST Action", a network that aims to promote the development of cold plasma in Europe, to carry out the research carried out to date on patients.
-
Describe an epigenetic protein associated with the metastatic process in Ewing's Sarcoma
A study with Dr. Jaume Mora (IRSJD) team participation and led by the Molecular Pathology of Sarcomas group of the Seville Institute of Biomedicine (IBiS) has described that the G9a protein would be associated with the development of metastases in Ewing's Sarcoma. Therefore, the overexpression of this protein would indicate an adverse prognosis.
-
EDIT-B Consortium validating innovative blood diagnostic test for bipolar disorder
Dr. Josep Maria Haro (IRSJD) and his research group participating in EDIT-B Consortium, supported by the European Institute of Innovation and Technology for Health (EIT Health). This newly formed European public-private partnership aims at advancing precision psychiatry by introducing biology into clinical routine.
-
Institut de Recerca Sant Joan de Déu joins the european platform EBRAIN
Institut de Recerca Sant Joan de Déu (IRSJD) strengthens its european position in the neuroscience’s field and the human brain’s study with its incorporation to the EBRAINS platform. A digital research infrastructure, created by the Human Brain Project (HBP) and partly funded by the European Union, which brings together a wide range of data and tools for brain research.
-
Supplementation with dopamine and serotonin precursors could have neuroprotective effects in children with early-onset epilepsy
A team of researchers at the Institut de Recerca Sant Joan de Déu shows that supplementation with neurotransmitters such as dopamine and serotonin could protect the brains of children under the age of 3 with early-onset epilepsy. The article was published in the scientific journal Developmental Medicine & Child Neurology.
-
Dementia cases could triple by 2050 if countries do not address the risk factors
According to a study published in The Lancet Public Health, the number of people with dementia could triple by 2050. This study is conducted by an international research team with the participation of Dr. Ai Koyanagi and Dr. Jacob Louis of Epidemiology of Mental Disorders and Aging from IRSJD.
-
Researchers discover a key factor that predicts COVID-19 disease severity
A study led by Drs. Laia Alsina and Iolanda Jordan from the IRSJD evidences a key factor that predicts the severity of COVID-19: an alteration of the first immune response to SARS-CoV-2 infection, in key molecules in the anti-infective response. The study has been published in open access in the journal iScience.
-
Mitochondria-lysosome contacts: a new cell phenotype in neurogenetic diseases
The Neurogenetics and Molecular Medicine research group of the Institut de Recerca Sant Joan de Déu (IRSJD), in collaboration with the Neuromuscular Pathology Unit of the SJD Barcelona Children's Hospital (HSJD), has studied the pathophysiology of mitochondrial dynamics and mitochondrial- lysosome contacts in cells from patients with neurogenetic diseases. The article has been published in the journal Frontiers in Neuroscience.
-
61% of people with early psychotic episodes have experienced childhood trauma
A study published in the Journal of Psychiatric Research and conducted by Regina Vila, a predoctoral researcher, and led by Dr. Judith Usall, co-coordinator of the Ethiopathogenesis and Treatment of Severe Mental Disorders (MERITT) group at the Institut de Recerca Sant Joan de Déu, analyzes factors and sociodemographic variables that may influence the onset and evolution of a first episode psychotic.
